Table 1. Patients characteristics with univariate and multivariate analysis of prognostic factors for survival.
| Characteristics |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| N (%) | Overall survival at 3 years | P-value | Hazard ratio | 95% CI | P-value | |
| Age at transplant | ||||||
| ⩽47 | 269 (51) | 0.759 | 1.00 | |||
| >47 | 254 (49) | 1.01 | 0.83–1.23 | 0.924 | ||
| Sex | ||||||
| Male | 265 (51) | 0.15 | 0.9088 | 1.00 | ||
| Female | 258 (49) | 0.18 | 0.90 | 0.75–1.07 | 0.233 | |
| Diagnosis | ||||||
| De novo | 370 (71) | 0.16 | 0.0201 | 1.00 | ||
| Secondary to MDS/CMML | 120 (23) | 0.02 | 1.01 | 0.79–1.29 | 0.953 | |
| Secondary to CMN/therapy-related | 28 (5) | 0.08 at 1.5 yrs | 1.87 | 1.21–2.88 | 0.005 | |
| Missing | 5 (1) | 3.80 | 1.49–9.71 | 0.005 | ||
| Disease status at transplant | ||||||
| PRF | 166 (32) | 0.10 | 0.0008 | 1.00 | ||
| Untreated I relapse | 44 (8) | 0.26 | 1.94 | 0.72–5.19 | 0.187 | |
| Untreated MDS-related AML | 27 (5) | 0.57 | 0.85 | 0.33–2.18 | 0.737 | |
| Refractory I relapse | 179 (34) | 0.16 | 1.95 | 0.77–4.92 | 0.156 | |
| > I relapse | 77 (15) | 0.12 | 2.38 | 0.91–6.19 | 0.076 | |
| Missing | 30 (6) | 2.49 | 0.96–6.49 | 0.061 | ||
| Previous transplant in CR | ||||||
| Autologous | 58 (55) | 0.21 | 0.8992 | — | — | — |
| Allogeneic | 47 (45) | 0.12 | — | — | — | |
| Duration first CR | ||||||
| <6 months | 137 (46) | 0.09 | 0.023 | 1.00 | ||
| ⩾6 months | 136 (45) | 0.24 | 1.32 | 1.02–1.70 | 0.032 | |
| Missing | 27 (9) | 1.31 | 0.84–2.03 | 0.230 | ||
| Chemotherapy cycles for primary refractory | ||||||
| 1 | 34 (20) | 0.18 | 0.0062 | 1.00 | ||
| ⩾2 | 126 (76) | 0.07 | 1.68 | 1.12–2.52 | 0.013 | |
| Missing | 6 (4) | 0.86 | 0.34–2.17 | 0.755 | ||
| Cytogenetics/ molecular biology | ||||||
| Favorable/intermediate I | 235 (45) | 0.20 | 0.0484 | 1.00 | ||
| Intermediate II/adverse | 178 (34) | 0.11 | 1.29 | 1.05–1.59 | 0.014 | |
| Missing | 110 (21) | 1.03 | 0.79–1.34 | 0.819 | ||
| Blasts at transplant | ||||||
| BM blasts <25% or no blasts in PB | 197 (38) | 0.26 | 0.0000 | 1.00 | ||
| BM blasts ⩾25% or any level in PB | 218 (42) | 0.12 | 1.46 | 1.19–1.80 | 0.000 | |
| Missing | 108 (20) | 1.30 | 0.98–1.73 | 0.072 | ||
| Karnofsky performance score at transplant | ||||||
| <90 | 177 (34) | 0.11 | 0.0000 | 1.00 | ||
| ⩾90 | 284 (54) | 0.21 | 1.52 | 1.24–1.87 | 0.000 | |
| Missing | 62 (12) | 1.47 | 1.10–1.96 | 0.010 | ||
| Graft type | ||||||
| Bone marrow | 148 (28) | 0.12 | 0.1515 | — | — | — |
| Peripheral stem cells | 342 (65.5) | 0.18 | — | — | — | |
| Cord blood | 33 (6.5) | 0.16 | — | — | — | |
| Donor-recipient HLA-match | ||||||
| Identical sibling /matched unrelated | 362 (69) | 0.19 | 0.0015 | 1.00 | ||
| Cord blood | 33 (6) | 0.16 | 1.59 | 1.08–2.34 | 0.020 | |
| Haplo/mismatched unrelated | 128 (25) | 0.09 | 1.59 | 1.28–1.98 | 0.000 | |
| Donor-recipient sex | ||||||
| M-M/F-F | 270 (52) | 0.18 | 0.6215 | — | — | — |
| M-F | 147 (29) | 0.18 | — | — | — | |
| F–M | 99 (19) | 0.13 | — | — | — | |
| Missing | 7 (1) | — | — | — | ||
| Donor anti-CMV antibodies | ||||||
| Positive | 312 (60) | 0.17 | 0.8963 | 1.00 | ||
| Negative | 160 (31) | 0.18 | 1.03 | 0.84–1.26 | 0.786 | |
| Missing | 51 (9) | 1.35 | 0.81–2.24 | 0.248 | ||
| Patient anti-CMV antibodies | ||||||
| Positive | 421 (80) | 0.18 | 0.1908 | 1.00 | ||
| Negative | 61 (12) | 0.17 | 1.42 | 1.07–1.88 | 0.015 | |
| Missing | 41 (8) | 0.81 | 0.45–1.45 | 0.473 | ||
| Conditioning regimen | ||||||
| RIC | 191 (37) | 0.16 | 0.9511 | 1.00 | ||
| MAC | 324 (62) | 0.17 | 0.96 | 0.79–1.17 | 0.690 | |
| Missing | 8 (2) | 1.12 | 0.50–2.53 | 0.780 | ||
| Type of conditioning | ||||||
| Busulfan/TBI> 600 Gy | 288 (55) | 0.13 | 0.1614 | — | — | — |
| Others | 219 (42) | 0.19 | — | — | — | |
| Missing | 16 (3) | — | — | — | ||
| GVHD prophylaxis | ||||||
| Ex vivo T-cell depletion | 42 (8) | 0.05 | 0.0370 | — | — | — |
| (Tacrolimus or CsA)+MTX±other | 307 (59) | 0.18 | — | — | — | |
| (Tacrolimus or CsA)±other | 77 (15) | 0.17 | — | — | — | |
| Other | 50 (10) | 0.25 | — | — | — | |
| Missing | 47 (9) | — | — | — | ||
| T-cell depletion in vivo | ||||||
| No T-cell depletion in vivo | 249 (48) | 0.19 | 0.1220 | — | — | — |
| ATG/ALG/Campath | 196 (37) | 0.17 | — | — | — | |
| Missing | 78 (15) | — | — | — | ||
| Acute GVHD | ||||||
| No | 273 (52) | 0.15 | — | — | — | |
| Yes | 228 (44) | — | — | — | ||
| Grade 1 | 91 (40) | 0.21 | 0.0000 | — | — | — |
| Grade 2 | 71 (31) | 0.28 | — | — | — | |
| Grade 3 | 41 (18) | 0.07 | — | — | — | |
| Grade 4 | 25 (11) | 0.04 | — | — | — | |
| Missing | 22 (4) | — | — | — | ||
| Chronic GVHD | ||||||
| No | 286 (55) | 0.10 | 0.0000 | — | — | — |
| Yes | 126 (24) | 0.39 | — | — | — | |
| Missing | 111 (21) | |||||
Abbreviations: ALG, anti-lymphocyte-globuline; AML, acute myeloid leukemia; ATG, anti-tymocyte-globuline; BM, bone marrow; CMML, chronic myelomonocytic leukemia; CMN, chronic myeloproliferative neoplasm; CMV, cytomegalovirus; CR, complete remission; CsA, cyclosporine; GVHD, graft versus host disease; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MTX, methotrexate; PB, peripheral blood; PRF, primary refractory; RIC, reduced-intensity conditioning; TBI, total body irradiation.